| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
8,906 |
7,378 |
$1.64M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
6,969 |
5,431 |
$1.19M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
3,037 |
2,393 |
$1.16M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
3,321 |
1,594 |
$626K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
4,369 |
3,117 |
$575K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
2,505 |
1,888 |
$563K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,943 |
2,595 |
$536K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,541 |
1,734 |
$466K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
9,109 |
6,667 |
$227K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,825 |
2,493 |
$222K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,397 |
1,259 |
$112K |
| 80053 |
Comprehensive metabolic panel |
12,619 |
10,002 |
$107K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
3,467 |
3,001 |
$93K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
349 |
294 |
$82K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,879 |
1,601 |
$81K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
316 |
250 |
$76K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
948 |
584 |
$75K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
13,214 |
9,841 |
$68K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,035 |
1,823 |
$67K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,938 |
1,724 |
$66K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,872 |
1,659 |
$62K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
3,922 |
3,207 |
$62K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
352 |
317 |
$59K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
166 |
154 |
$54K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
1,041 |
951 |
$53K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
2,760 |
999 |
$52K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
731 |
675 |
$50K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,616 |
1,302 |
$41K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,219 |
1,013 |
$38K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
1,198 |
1,073 |
$37K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,800 |
2,541 |
$36K |
| 73562 |
|
1,070 |
760 |
$36K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
104 |
75 |
$35K |
| 76830 |
Ultrasound, transvaginal |
266 |
233 |
$33K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
996 |
845 |
$32K |
| 81025 |
|
4,054 |
3,518 |
$31K |
| 80061 |
Lipid panel |
2,451 |
2,273 |
$29K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
4,118 |
3,503 |
$29K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
131 |
79 |
$27K |
| 80050 |
General health panel |
1,724 |
1,580 |
$27K |
| 71046 |
Radiologic examination, chest; 2 views |
1,858 |
1,395 |
$27K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
293 |
221 |
$23K |
| 84484 |
|
3,647 |
2,308 |
$22K |
| 81001 |
|
8,158 |
6,863 |
$22K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,493 |
2,300 |
$20K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,051 |
2,283 |
$19K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,625 |
2,995 |
$19K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
383 |
174 |
$19K |
| 85027 |
|
3,360 |
2,776 |
$18K |
| 83690 |
|
3,303 |
2,777 |
$17K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
626 |
560 |
$15K |
| 83735 |
|
3,869 |
2,829 |
$14K |
| 84439 |
|
1,485 |
1,345 |
$14K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,123 |
1,027 |
$12K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,990 |
2,523 |
$12K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
49 |
39 |
$11K |
| 87634 |
|
183 |
163 |
$11K |
| G0378 |
Hospital observation service, per hour |
628 |
293 |
$11K |
| 83880 |
|
793 |
670 |
$11K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
38 |
36 |
$10K |
| 96523 |
|
286 |
149 |
$9K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
93 |
72 |
$9K |
| 87186 |
|
1,328 |
1,063 |
$9K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
75 |
66 |
$8K |
| 87077 |
|
1,382 |
1,099 |
$8K |
| 11721 |
|
651 |
315 |
$7K |
| 73030 |
|
285 |
186 |
$7K |
| 85610 |
|
2,807 |
2,222 |
$7K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
12 |
12 |
$7K |
| 36415 |
Collection of venous blood by venipuncture |
22,032 |
16,601 |
$7K |
| 85730 |
|
2,046 |
1,736 |
$6K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
96 |
79 |
$6K |
| 82728 |
|
601 |
548 |
$6K |
| 36591 |
|
187 |
90 |
$5K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,461 |
1,696 |
$5K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
463 |
148 |
$5K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
5,391 |
4,183 |
$5K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
177 |
164 |
$5K |
| 73610 |
|
219 |
171 |
$4K |
| 82962 |
|
2,270 |
1,290 |
$4K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
77 |
26 |
$4K |
| 0011A |
|
138 |
125 |
$4K |
| 71045 |
Radiologic examination, chest; single view |
3,991 |
2,785 |
$4K |
| 0012A |
|
131 |
117 |
$4K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
218 |
94 |
$4K |
| 93017 |
|
13 |
13 |
$4K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
15 |
13 |
$4K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
18 |
13 |
$3K |
| 85379 |
|
535 |
481 |
$3K |
| 83605 |
|
618 |
439 |
$3K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
120 |
103 |
$3K |
| 84145 |
|
342 |
287 |
$3K |
| 84703 |
|
461 |
404 |
$3K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
98 |
84 |
$3K |
| 73630 |
|
136 |
109 |
$2K |
| 93975 |
|
14 |
14 |
$2K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,893 |
3,291 |
$2K |
| 82570 |
|
442 |
408 |
$2K |
| 87040 |
|
363 |
170 |
$2K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
37 |
25 |
$1K |
| 86140 |
|
413 |
353 |
$1K |
| 76801 |
|
18 |
14 |
$1K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
68 |
50 |
$1K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,806 |
1,448 |
$1K |
| 73502 |
|
55 |
42 |
$1K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
3,343 |
2,636 |
$1K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
6,243 |
3,985 |
$995.92 |
| J7050 |
Infusion, normal saline solution, 250 cc |
6,642 |
3,719 |
$989.23 |
| 0071A |
|
14 |
14 |
$755.16 |
| 83550 |
|
108 |
106 |
$742.27 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
118 |
103 |
$732.08 |
| 84100 |
|
305 |
233 |
$722.12 |
| 84702 |
|
46 |
36 |
$695.05 |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
14 |
13 |
$690.06 |
| 86850 |
|
187 |
156 |
$600.28 |
| 83540 |
|
110 |
107 |
$567.95 |
| 82043 |
|
103 |
100 |
$560.82 |
| 99152 |
|
96 |
85 |
$552.31 |
| 99215 |
Prolong outpt/office vis |
27 |
24 |
$459.67 |
| 82550 |
|
123 |
87 |
$427.67 |
| 96127 |
|
85 |
82 |
$405.87 |
| 86803 |
|
29 |
29 |
$392.05 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
15 |
13 |
$350.52 |
| 81003 |
|
151 |
131 |
$349.09 |
| 74018 |
|
14 |
12 |
$341.14 |
| 73130 |
|
16 |
12 |
$336.84 |
| 82607 |
|
28 |
25 |
$327.60 |
| 87581 |
|
15 |
13 |
$310.23 |
| 87486 |
|
15 |
13 |
$310.23 |
| 85651 |
|
91 |
75 |
$300.75 |
| 82950 |
|
46 |
45 |
$296.34 |
| J2704 |
Injection, propofol, 10 mg |
3,822 |
1,906 |
$291.04 |
| 85018 |
|
110 |
94 |
$282.90 |
| 86901 |
|
152 |
115 |
$264.43 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
867 |
434 |
$258.72 |
| 0001A |
|
16 |
12 |
$254.10 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
145 |
97 |
$252.74 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
3,809 |
2,847 |
$246.58 |
| 87210 |
|
42 |
40 |
$222.00 |
| 85007 |
|
70 |
57 |
$205.00 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
2,961 |
2,384 |
$165.86 |
| 97162 |
|
14 |
13 |
$165.06 |
| 87070 |
|
26 |
25 |
$146.63 |
| 85652 |
|
72 |
68 |
$144.99 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
42 |
36 |
$123.95 |
| 82746 |
|
14 |
12 |
$122.06 |
| 86900 |
|
72 |
54 |
$111.24 |
| 99153 |
Mod sedat endo service >5yrs |
80 |
72 |
$98.68 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
1,006 |
804 |
$77.34 |
| 83615 |
|
15 |
12 |
$56.16 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
646 |
389 |
$36.30 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,697 |
2,947 |
$25.60 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
4,590 |
2,335 |
$16.27 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
403 |
181 |
$15.96 |
| 96160 |
|
12 |
12 |
$12.60 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
68 |
63 |
$2.55 |
| A9577 |
Injection, gadobenate dimeglumine (multihance), per ml |
174 |
155 |
$2.44 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
219 |
158 |
$2.08 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
106 |
99 |
$1.79 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,102 |
1,283 |
$1.37 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
566 |
353 |
$1.11 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
495 |
363 |
$0.45 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
375 |
322 |
$0.41 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
826 |
644 |
$0.29 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
271 |
238 |
$0.24 |
| 96376 |
|
258 |
159 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
144 |
69 |
$0.00 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
115 |
111 |
$0.00 |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
75 |
66 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
15 |
12 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
19 |
19 |
$0.00 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
41 |
37 |
$0.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
48 |
40 |
$0.00 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
25 |
12 |
$0.00 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
237 |
215 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
142 |
117 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
411 |
301 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
493 |
148 |
$0.00 |
| 90662 |
|
12 |
12 |
$0.00 |
| 92015 |
Determination of refractive state |
15 |
13 |
$0.00 |